EPIDEMIOLOGY AND HEALTH DATA INSIGHTS
Review Article
Apr 12, 2026 11 5

Anti-Virulence Therapy as a Low-Resistance Alternative to Conventional Antibiotics: Mechanistic Insights, Evolutionary Considerations, and Translational Prospects

Adepeju Kafayat Olowookere 1 * ,
Victoria Ifeyinwa Uwakwe 2,
Sylviastella Favour Peteranaba 3
1 Department of Nanoscience, University of North Carolina at Greensboro, Greensboro, NC, USA2 Department of Biology, Bemidji State University, Bemidji, MN, USA3 Department of Health Science, Public Health University of New Haven, West Haven, CT, USA* Corresponding Author
Epidemiology and Health Data Insights, 2(3), 2026, ehdi036, https://doi.org/10.63946/ehdi/18354
Publication date: Apr 12, 2026
Full Text (PDF)

ABSTRACT

The growing pace of antimicrobial resistance (AMR) is a serious threat to modern infectious disease control as it has significantly undermined the clinical value of the traditional antibiotics. Traditional antimicrobial agents, which act by preventing the growth of bacteria or causing cell death, place a lot of selection pressure on the microbial population, therefore, promoting the rapid emergence and spread of resistance determinants. Besides spurring the evolution of resistance, such strategies often destabilize commensal microbiota and help transfer resistance genes between different bacteria of various species. These restrictions have shown that there is an urgent need to establish alternative treatment measures capable of reducing infections and reducing evolutionary pressures that promote resistance. Anti-virulence therapy (AVT) has developed as an exciting paradigm which has sought to lay emphasis on the molecular aspects of bacterial pathogenicity, as opposed to microbial viability. AVTs are designed to disrupt virulence-related processes such as quorum sensing, toxin secretion, host adhesion, immune evasion, and nutrient acquisition by selectively interrupting virulence in endotoxin-producing bacteria with the aim of attenuating virulence and promoting host-mediated clearance without necessarily endangering the survival of bacteria. It is theorized that this mechanistic difference will decrease the selective advantage provided to resistant variants, which may retard the tempo of resistance emergence and dissemination in bacterial populations. In this case, we will analyze the mechanistic foundations of bacterial virulence and will compare the existing anti-virulence therapies used as therapeutic approaches and their application in an evolutionary context. We also evaluate the new preclinical and clinical findings under the effectiveness of AVTs, along with the most important translational obstacles in terms of pharmacological optimization, target specificity, and regulatory validation. Together, these observations provide support to anti-virulence interventions as complementary or alternative therapies to conventional antibiotics in the treatment of multidrug-resistant infections, and highlight the necessity of interdisciplinary collaboration in order to support the adoption of such interventions into new-generation antimicrobial treatment programs.

KEYWORDS

Anti-Virulence Therapy Antimicrobial Resistance Quorum Sensing Multidrug-Resistant Pathogens Biofilm Disruption

CITATION (Vancouver)

Olowookere AK, Uwakwe VI, Peteranaba SF. Anti-Virulence Therapy as a Low-Resistance Alternative to Conventional Antibiotics: Mechanistic Insights, Evolutionary Considerations, and Translational Prospects. Epidemiology and Health Data Insights. 2026;2(3):ehdi036. https://doi.org/10.63946/ehdi/18354
APA
Olowookere, A. K., Uwakwe, V. I., & Peteranaba, S. F. (2026). Anti-Virulence Therapy as a Low-Resistance Alternative to Conventional Antibiotics: Mechanistic Insights, Evolutionary Considerations, and Translational Prospects. Epidemiology and Health Data Insights, 2(3), ehdi036. https://doi.org/10.63946/ehdi/18354
Harvard
Olowookere, A. K., Uwakwe, V. I., and Peteranaba, S. F. (2026). Anti-Virulence Therapy as a Low-Resistance Alternative to Conventional Antibiotics: Mechanistic Insights, Evolutionary Considerations, and Translational Prospects. Epidemiology and Health Data Insights, 2(3), ehdi036. https://doi.org/10.63946/ehdi/18354
AMA
Olowookere AK, Uwakwe VI, Peteranaba SF. Anti-Virulence Therapy as a Low-Resistance Alternative to Conventional Antibiotics: Mechanistic Insights, Evolutionary Considerations, and Translational Prospects. Epidemiology and Health Data Insights. 2026;2(3), ehdi036. https://doi.org/10.63946/ehdi/18354
Chicago
Olowookere, Adepeju Kafayat, Victoria Ifeyinwa Uwakwe, and Sylviastella Favour Peteranaba. "Anti-Virulence Therapy as a Low-Resistance Alternative to Conventional Antibiotics: Mechanistic Insights, Evolutionary Considerations, and Translational Prospects". Epidemiology and Health Data Insights 2026 2 no. 3 (2026): ehdi036. https://doi.org/10.63946/ehdi/18354
MLA
Olowookere, Adepeju Kafayat et al. "Anti-Virulence Therapy as a Low-Resistance Alternative to Conventional Antibiotics: Mechanistic Insights, Evolutionary Considerations, and Translational Prospects". Epidemiology and Health Data Insights, vol. 2, no. 3, 2026, ehdi036. https://doi.org/10.63946/ehdi/18354

REFERENCES

  1. Salam MdA, Al-Amin MdY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial resistance: a growing serious threat to global public health. Healthcare (Basel). 2023;11:1946. https://doi.org/10.3390/healthcare11131946
  2. Coque TM, Cantón R, Pérez-Cobas AE, Fernández-de-Bobadilla MD, Baquero F. Antimicrobial resistance in the global health network: known unknowns and challenges for efficient responses in the 21st century. Microorganisms. 2023;11:1050. https://doi.org/10.3390/microorganisms11041050
  3. Brüssow H. The antibiotic resistance crisis and the development of new antibiotics. Microb Biotechnol. 2024;17:e14510. https://doi.org/10.1111/1751-7915.14510
  4. Lawal OP, Babatunde JO, Owusu-Ansah S, et al. Antibiogram and molecular characterization of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a Nigerian teaching hospital. Microbes Infect Chemother. 2025;5:e2305. https://doi.org/10.54034/mic.e2305
  5. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review. Pharmaceuticals (Basel). 2023;16:1615. https://doi.org/10.3390/ph16111615
  6. Lawal OP, Ayomide IT, Kwame AB, et al. Prevalence of extended-spectrum beta-lactamase-producing bacterial species isolated from handbags of women in Abeokuta, Nigeria. South Asian J Res Microbiol. 2024;18:12–24. https://doi.org/10.9734/sajrm/2024/v18i11396
  7. Matei AT, Visan AI. Mechanism, efficacy, and safety of natural antibiotics. Antibiotics (Basel). 2025;14. https://doi.org/10.3390/antibiotics14100981
  8. Wachino J. Horizontal gene transfer systems for spread of antibiotic resistance in Gram-negative bacteria. Microbiol Immunol. 2025;69:367–76. https://doi.org/10.1111/1348-0421.13222
  9. Lawal OP, Njoba CF, Olorunkosebi MT, et al. Microplastics as emerging reservoirs of antimicrobial resistance: clinical relevance and environmental mechanisms. J Clin Exp Investig. 2025;16:em00852. https://doi.org/10.29333/jcei/17401
  10. Sharma S, Mohler J, Mahajan SD, Schwartz SA, Bruggemann L, Aalinkeel R. Microbial biofilm: a review on formation, infection, antibiotic resistance, control measures, and innovative treatment. Microorganisms. 2023;11. https://doi.org/10.3390/microorganisms11061614
  11. Yarahmadi A, Najafiyan H, Yousefi MH, et al. Beyond antibiotics: exploring multifaceted approaches to combat bacterial resistance in the modern era: a comprehensive review. Front Cell Infect Microbiol. 2025;15. https://doi.org/10.3389/fcimb.2025.1493915
  12. Barber MF, Fitzgerald JR. Mechanisms of host adaptation by bacterial pathogens. FEMS Microbiol Rev. 2024;48:fuae019. https://doi.org/10.1093/femsre/fuae019
  13. Chebotar I, Azizov I, Edelstein M, Kozlov R. Detection of virulence factors in opportunistic bacteria: advances, challenges, and practical implementation. Front Microbiol. 2025;16:1638925. https://doi.org/10.3389/fmicb.2025.1638925
  14. Soni J, Sinha S, Pandey R. Understanding bacterial pathogenicity: a closer look at the journey of harmful microbes. Front Microbiol. 2024;15. https://doi.org/10.3389/fmicb.2024.1370818
  15. Zhao X, Yu Z, Ding T. Quorum-sensing regulation of antimicrobial resistance in bacteria. Microorganisms. 2020;8:425. https://doi.org/10.3390/microorganisms8030425
  16. Luo W, Li Y, Chen S, Liang Y, Liu X. Roles and regulation of quorum sensing of acidophiles in bioleaching: a review. Microorganisms. 2024;12. https://doi.org/10.3390/microorganisms12030422
  17. Popoff MR. Overview of bacterial protein toxins from pathogenic bacteria: mode of action and insights into evolution. Toxins (Basel). 2024;16. https://doi.org/10.3390/toxins16040182
  18. Lin Q, Lin S, Fan Z, Liu J, Ye D, Guo P. A review of the mechanisms of bacterial colonization of the mammal gut. Microorganisms. 2024;12. https://doi.org/10.3390/microorganisms12051026
  19. Gu Y, Wang HY, Wang YS, Wang L, Jia XM. Challenges posed by fungi to host immunity: mechanisms of immune evasion. hLife. 2026. https://doi.org/10.1016/j.hlife.2025.12.008
  20. Murdoch CC, Skaar EP. Nutritional immunity: the battle for nutrient metals at the host–pathogen interface. Nat Rev Microbiol. 2022;20:657–70. https://doi.org/10.1038/s41579-022-00745-6
  21. Hussaini IM, Oyewole OA, Sulaiman MA, et al. Microbial anti-biofilms: types and mechanism of action. Res Microbiol. 2024;175:104111. https://doi.org/10.1016/j.resmic.2023.104111
  22. Lawal O, Orenolu IO, Ajobiewe MA, et al. Hospital-acquired infections in the age of antimicrobial resistance and smart surveillance. Aust J Biomed Res. 2025;1:aubm002. https://doi.org/10.63946/aubiomed/16759
  23. Patel K, Panchal R, Sakariya B, et al. Combatting antibiotic resistance by exploring the promise of quorum quenching in targeting bacterial virulence. Microbe. 2025;6:100224. https://doi.org/10.1016/j.microb.2024.100224
  24. Wang Y, Zeng M, Xia L, et al. Bacterial strategies for immune systems: role of the type VI secretion system. Int Immunopharmacol. 2023;114:109550. https://doi.org/10.1016/j.intimp.2022.109550
  25. Pokharel P, Dhakal S, Dozois CM. The diversity of Escherichia coli pathotypes and vaccination strategies against this versatile bacterial pathogen. Microorganisms. 2023;11. https://doi.org/10.3390/microorganisms11020344
  26. Pecoraro C, Carbone D, Parrino B, Cascioferro S, Diana P. Recent developments in the inhibition of bacterial adhesion as a promising anti-virulence strategy. Int J Mol Sci. 2023;24. https://doi.org/10.3390/ijms24054872
  27. Wang D, Wang L, Liu Q, Zhao Y. Virulence factors in biofilm formation and therapeutic strategies for Staphylococcus aureus: a review. Anim Zoonoses. 2025;1:188–202. https://doi.org/10.1016/j.azn.2024.11.003
  28. Lan P, Lu Y, Fu Y, Yu Y, Zhou J. Siderophores and beyond: a comprehensive review of iron acquisition in Klebsiella pneumoniae. Virulence. 2025;16:2550621. https://doi.org/10.1080/21505594.2025.2550621
  29. Elbaiomy RG, El-Sappah AH, Guo R, et al. Antibiotic resistance: a genetic and physiological perspective. MedComm (2020). 2025;6:e70447. https://doi.org/10.1002/mco2.70447
  30. Cylke C, Si F, Banerjee S. Effects of antibiotics on bacterial cell morphology and their physiological origins. Biochem Soc Trans. 2022;50:1269–79. https://doi.org/10.1042/BST20210894
  31. Mahmud HA, Wakeman CA. Navigating collateral sensitivity: insights into the mechanisms and applications of antibiotic resistance trade-offs. Front Microbiol. 2024;15. https://doi.org/10.3389/fmicb.2024.1478789
  32. Rezzoagli C, Archetti M, Mignot I, et al. Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa. PLoS Biol. 2020;18:e3000805. https://doi.org/10.1371/journal.pbio.3000805
  33. Lissens M, Joos M, Lories B, Steenackers HP. Evolution-proof inhibitors of public good cooperation: a screening strategy inspired by social evolution theory. FEMS Microbiol Rev. 2022;46:fuac019. https://doi.org/10.1093/femsre/fuac019
  34. Liu F, Hu M, Zhang Z, et al. Dickeya manipulates multiple quorum-sensing systems to control virulence and collective behaviors. Front Plant Sci. 2022;13. https://doi.org/10.3389/fpls.2022.838125
  35. Belay WY, Getachew M, Tegegne BA, et al. Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: a review. Front Pharmacol. 2024;15. https://doi.org/10.3389/fphar.2024.1444781
  36. Hasanuzzaman M, Bang CS, Gong EJ. Antibiotic resistance of Helicobacter pylori: mechanisms and clinical implications. J Korean Med Sci. 2024;39:e44. https://doi.org/10.3346/jkms.2024.39.e44
  37. Elshobary ME, Badawy NK, Ashraf Y, et al. Combating antibiotic resistance: mechanisms, multidrug-resistant pathogens, and novel therapeutic approaches: an updated review. Pharmaceuticals (Basel). 2025;18. https://doi.org/10.3390/ph18030402
  38. Nwosu PC, Egwuatu EC, Wright AK-A, et al. Diabetic foot ulcers in Africa: a systematic review of microbial profiles and clinical outcomes in the context of multidrug resistance. Epidemiol Health Data Insights. 2025;1:ehdi022. https://doi.org/10.63946/ehdi/17471
  39. Kitpipit W, Scholfield CN, Sangkanu S, et al. Virulence factors and quorum sensing as targets of new therapeutic options by plant-derived compounds against bacterial infections. Vet World. 2023;16:1346–55. https://doi.org/10.14202/vetworld.2023.1346-1355
  40. Touaitia R, Mairi A, Ibrahim NA, et al. Staphylococcus aureus: a review of the pathogenesis and virulence mechanisms. Antibiotics (Basel). 2025;14. https://doi.org/10.3390/antibiotics14050470
  41. Zhao M, Rong D, Chen L, et al. Beyond antibiotics: therapeutic strategies utilizing probiotics and bacteriophages against drug-resistant Staphylococcus aureus. Microorganisms. 2026;14. https://doi.org/10.3390/microorganisms14020344
  42. Adedokun AI, Adigun OA, Ibrahim AM, et al. Exploring immunotherapeutic strategies for bacterial and viral diseases. Explor Immunol. 2025;5:1003202. https://doi.org/10.37349/ei.2025.1003202
  43. Nwokedi VU, Akanbi OO, Ayo-Ige BA, et al. Evaluating the role and impact of international collaboration and partnerships on the control, prevention, and elimination of parasitic diseases: a global health perspective. Aust J Biomed Res. 2025;1:aubm009. https://doi.org/10.63946/aubiomed/17426
  44. Merker M, Tueffers L, Vallier M, et al. Evolutionary approaches to combat antibiotic resistance: opportunities and challenges for precision medicine. Front Immunol. 2020;11:1938. https://doi.org/10.3389/fimmu.2020.01938
  45. Rosignoli S, Lustrino E, Shevchuk O, et al. Bioinformatics-driven, plant-based antibiotic research against quorum sensing and biofilm formation in Pseudomonas aeruginosa and Escherichia coli multiresistant microbes. Biomolecules. 2026;16. https://doi.org/10.3390/biom16020197
  46. El-Sayed SE, Messiha AA, Zafer M. Effective alternative strategies to combat challenges associated with MDR bacterial infections: drug repurposing, role of artificial intelligence, and novel therapeutic options. J Infect Public Health. 2026;19:103058. https://doi.org/10.1016/j.jiph.2025.103058
  47. Lawal OP, Opara IJ, Ayo-Ige BA, et al. Artificial intelligence-integrated biosensors for antimicrobial resistance detection and surveillance: a review and future perspectives for global biosecurity. Cureus. 2025;17. https://doi.org/10.7759/cureus.98098
  48. Mulat M, Banicod RJS, Tabassum N, et al. Application of artificial intelligence in microbial drug discovery: unlocking new frontiers in biotechnology. J Microbiol Methods. 2025;237:107232. https://doi.org/10.1016/j.mimet.2025.107232

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.